These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 21239475)

  • 1. CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors.
    Anderson VE; Walton MI; Eve PD; Boxall KJ; Antoni L; Caldwell JJ; Aherne W; Pearl LH; Oliver AW; Collins I; Garrett MD
    Cancer Res; 2011 Jan; 71(2):463-72. PubMed ID: 21239475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide].
    Jobson AG; Lountos GT; Lorenzi PL; Llamas J; Connelly J; Cerna D; Tropea JE; Onda A; Zoppoli G; Kondapaka S; Zhang G; Caplen NJ; Cardellina JH; Yoo SS; Monks A; Self C; Waugh DS; Shoemaker RH; Pommier Y
    J Pharmacol Exp Ther; 2009 Dec; 331(3):816-26. PubMed ID: 19741151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARP inhibition during alkylation-induced genotoxic stress signals a cell cycle checkpoint response mediated by ATM.
    Carrozza MJ; Stefanick DF; Horton JK; Kedar PS; Wilson SH
    DNA Repair (Amst); 2009 Nov; 8(11):1264-72. PubMed ID: 19717351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based design of potent and selective 2-(quinazolin-2-yl)phenol inhibitors of checkpoint kinase 2.
    Caldwell JJ; Welsh EJ; Matijssen C; Anderson VE; Antoni L; Boxall K; Urban F; Hayes A; Raynaud FI; Rigoreau LJ; Raynham T; Aherne GW; Pearl LH; Oliver AW; Garrett MD; Collins I
    J Med Chem; 2011 Jan; 54(2):580-90. PubMed ID: 21186793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent.
    Nguyen D; Zajac-Kaye M; Rubinstein L; Voeller D; Tomaszewski JE; Kummar S; Chen AP; Pommier Y; Doroshow JH; Yang SX
    Cell Cycle; 2011 Dec; 10(23):4074-82. PubMed ID: 22101337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins.
    Huang M; Miao ZH; Zhu H; Cai YJ; Lu W; Ding J
    Mol Cancer Ther; 2008 Jun; 7(6):1440-9. PubMed ID: 18566216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crystal structure of checkpoint kinase 2 in complex with NSC 109555, a potent and selective inhibitor.
    Lountos GT; Tropea JE; Zhang D; Jobson AG; Pommier Y; Shoemaker RH; Waugh DS
    Protein Sci; 2009 Jan; 18(1):92-100. PubMed ID: 19177354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Context-dependent cell cycle checkpoint abrogation by a novel kinase inhibitor.
    Massey AJ; Borgognoni J; Bentley C; Foloppe N; Fiumana A; Walmsley L
    PLoS One; 2010 Oct; 5(10):e13123. PubMed ID: 20976184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibition.
    Höglund A; Strömvall K; Li Y; Forshell LP; Nilsson JA
    Cell Cycle; 2011 Oct; 10(20):3598-607. PubMed ID: 22030621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased cytotoxicity of an unusual DNA topoisomerase II inhibitor compound C-1305 toward HeLa cells with downregulated PARP-1 activity results from re-activation of the p53 pathway and modulation of mitotic checkpoints.
    Sabisz M; Wesierska-Gadek J; Skladanowski A
    Biochem Pharmacol; 2010 May; 79(10):1387-97. PubMed ID: 20067769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways.
    Mini E; Landini I; Lucarini L; Lapucci A; Napoli C; Perrone G; Tassi R; Masini E; Moroni F; Nobili S
    Oncol Res; 2017 Nov; 25(9):1441-1451. PubMed ID: 28429680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage.
    Boulton S; Kyle S; Durkacz BW
    Carcinogenesis; 1999 Feb; 20(2):199-203. PubMed ID: 10069454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alkylation DNA damage in combination with PARP inhibition results in formation of S-phase-dependent double-strand breaks.
    Heacock ML; Stefanick DF; Horton JK; Wilson SH
    DNA Repair (Amst); 2010 Aug; 9(8):929-36. PubMed ID: 20573551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural characterization of inhibitor complexes with checkpoint kinase 2 (Chk2), a drug target for cancer therapy.
    Lountos GT; Jobson AG; Tropea JE; Self CR; Zhang G; Pommier Y; Shoemaker RH; Waugh DS
    J Struct Biol; 2011 Dec; 176(3):292-301. PubMed ID: 21963792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiation of the novel topoisomerase I inhibitor indenoisoquinoline LMP-400 by the cell checkpoint and Chk1-Chk2 inhibitor AZD7762.
    Aris SM; Pommier Y
    Cancer Res; 2012 Feb; 72(4):979-89. PubMed ID: 22189968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a Bis-guanylhydrazone [4,4'-Diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a novel chemotype for inhibition of Chk2 kinase.
    Jobson AG; Cardellina JH; Scudiero D; Kondapaka S; Zhang H; Kim H; Shoemaker R; Pommier Y
    Mol Pharmacol; 2007 Oct; 72(4):876-84. PubMed ID: 17616632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chk1 is dispensable for G2 arrest in response to sustained DNA damage when the ATM/p53/p21 pathway is functional.
    Lossaint G; Besnard E; Fisher D; Piette J; Dulić V
    Oncogene; 2011 Oct; 30(41):4261-74. PubMed ID: 21532626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphorylation of p53 on Ser15 during cell cycle caused by Topo I and Topo II inhibitors in relation to ATM and Chk2 activation.
    Zhao H; Traganos F; Darzynkiewicz Z
    Cell Cycle; 2008 Oct; 7(19):3048-55. PubMed ID: 18802408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
    Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
    J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064.
    Bowman KJ; White A; Golding BT; Griffin RJ; Curtin NJ
    Br J Cancer; 1998 Nov; 78(10):1269-77. PubMed ID: 9823965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.